Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of paracetamol (acetaminophen) and dexketoprofen, the S(+)-enantiomer of the non-steroidal anti-inflammatory drug (NSAID) ketoprofen. Paracetamol acts primarily as a central analgesic and antipyretic, likely through the inhibition of cyclooxygenase (COX) enzymes in the central nervous system, thereby elevating the pain threshold. Dexketoprofen provides potent peripheral analgesic and anti-inflammatory effects by inhibiting both COX-1 and COX-2 enzymes, which reduces the synthesis of pro-inflammatory prostaglandins. This dual-action regimen is being evaluated by researchers at Kastamonu University for its efficacy in managing acute pain associated with isolated rib fractures, often in comparison or conjunction with physical therapy techniques like kinesiotaping.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + dexketoprofen.